Details of the Drug

General Information of Drug (ID: DMZI25U)

• Drug Name: PMID27109571-Compound-16
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 1:
  Molecular Weight (mw); 424.4
  Logarithm of the Partition Coefficient (xlogp); 5.2
  Rotatable Bond Count (rotbonds); 3
  Hydrogen Bond Donor Count (hbonddonor); 1
  Hydrogen Bond Acceptor Count (hbondacc); 8
• Chemical Identifiers:
  Formula: C22H19F3N6
  IUPAC Name: 4-phenyl-2-piperidin-1-yl-3-(2H-tetrazol-5-yl)-6-(trifluoromethyl)quinoline
  Canonical SMILES: C1CCN(CC1)C2=NC3=C(C=C(C=C3)C(F)(F)F)C(=C2C4=NNN=N4)C5=CC=CC=C5
  InChI: InChI=1S/C22H19F3N6/c23-22(24,25)15-9-10-17-16(13-15)18(14-7-3-1-4-8-14)19(20-27-29-30-28-20)21(26-17)31-11-5-2-6-12-31/h1,3-4,7-10,13H,2,5-6,11-12H2,(H,27,28,29,30)
  InChIKey: SUXQAVNHOCPUSH-UHFFFAOYSA-N
• Cross-matching ID:
  PubChem CID: 86683056
  TTD ID: D01CDK

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Fatty acid-binding protein 4 (FABP4)	TTHWMFZ	FABP4_HUMAN	Inhibitor	[1]
Fatty acid-binding protein 5 (FABP5)	TTNT2S6	FABP5_HUMAN	Inhibitor	[1]

References

• [1] Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76.